A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials.
about
Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.Advances in Statistical Approaches Oncology Drug Development.Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic ProfileDose escalation with over-dose and under-dose controls in Phase I/II clinical trials.Interactive Software "Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)" for Cancer Phase I Clinical Trials.Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicitiesRepeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma.Challenges and Innovations in Phase I Dose-Finding Designs for Molecularly Targeted Agents and Cancer Immunotherapies.Dose finding with continuous outcome in phase I oncology trials.Methodology and Application of Adaptive and Sequential Approaches in Contemporary Clinical Trials
P2860
Q30665810-352C2769-819B-48F1-A884-8EB1D6080725Q30757656-D5D4D871-2CA5-405A-8BE7-839F58E3E254Q30968729-B2DDBFEB-08CA-4D5A-B972-2970F591A6EEQ33714319-3FC84D9E-372C-4E27-AEF0-18E572B87D44Q35565672-A0EA6B53-F357-47BF-B81E-DBA2B68C75BCQ36261042-FDF9C044-B4C4-4C37-927D-CDD621F123EDQ36913166-18759EED-0E9F-42CA-8E1A-EB12403046FDQ36924666-846FA62E-2772-4C3B-89EA-672D33CA9429Q37270128-8A407C3A-EAB3-4A49-BC78-8FC5E4616C7DQ38648615-450D6781-1758-4861-B868-8B49A07A6CE6Q38763415-D5476678-4E97-4859-ABD4-4E2DB6260897Q39374749-62D202F5-B0D4-4A23-81BD-48CFF3DD05F9Q51010190-E26A6130-14AF-4146-BFCD-555070DBD109Q58910970-3C6DB134-8E0B-42D9-8401-846F67255CC5
P2860
A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
A novel toxicity scoring syste ...... le in Phase I clinical trials.
@en
type
label
A novel toxicity scoring syste ...... le in Phase I clinical trials.
@en
prefLabel
A novel toxicity scoring syste ...... le in Phase I clinical trials.
@en
P2093
P2860
P1476
A novel toxicity scoring syste ...... le in Phase I clinical trials.
@en
P2093
Mark D Krailo
Mourad Tighiouart
Stanley P Azen
Zhengjia Chen
P2860
P304
P356
10.1016/J.CCT.2010.05.010
P407
P577
2010-06-02T00:00:00Z